-
Mashup Score: 3
Bora Lim, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase II LITESPARK-029 trial (NCT06428396) of belzutifan, a HIF-2α inhibitor, with fulvestrant versus everolimus with fulvestrant or exemestane in patients with ER+/HER2- unresectable or metastatic breast cancer. Primary endpoints include progression-free survival (PFS) and secondary objectives include overall survival and clinical benefit. This trial aims to address resistance mechanisms and improve outcomes in advanced disease. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 9 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
📢1 week until all things GI cancer are debated virtually at #GDUGI2023! Keep an eye on https://t.co/ys1d8pDAKO for all the updates…💻 @GreatDebatesCME #GDUGI2023 #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/Bj1V9ui2l2
-
-
Mashup Score: 13SABCS 2024 Archives - VJOncology - 9 day(s) ago
VJOncology are excited to attend the upcoming 47th San Antonio Breast Cancer Symposium (SABCS) 2024, bringing you the highly-anticipated trial data and insightful perspectives from leading experts in breast cancer! This international scientific symposium allows for important interactions and exchanges between basic scientists and clinicians devoted to improved diagnosis and treatment of breast cancer. Stay tuned for our coverage of the meeting, and catch up on the 2023 meeting below! VJOncology are
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
Our Collaborators at @VJOncology are in San Antonio for #SABCS24 bringing you the highly-anticipated trial data and insightful perspectives from leading experts in #BreastCancer Find their Coverage here: https://t.co/yORESTUyvO Experts include @KalinskyKevin @matteolambe… https://t.co/7qtugUdaHG https://t.co/lruXvOrwc2
-
-
Mashup Score: 82141-V11: an anti-CD40 monoclonal antibody for tumor regression in patients with metastatic cancer - 9 day(s) ago
Juan Osorio, MD, Memorial Sloan Kettering Cancer Center, The Rockefeller University, New York, NY, introduces an in-human Phase I study (NCT04059588), which explored the efficacy and safety of 2141-V11, an anti-CD40 monoclonal antibody engineered to enhance the binding to the inhibitory receptor FcγRIIB, a critical interaction in the antitumor activity of antibodies. The study was developed to induce tumor regression whilst reducing drug-related toxicities in patients with metastatic cancer. This interview took place at the 39th Annual Meeting Society for Immunotherapy of Cancer 2024, Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥@juanosoriomd of @MSKCancerCenter discusses a Phase I study on 2141-V11, an anti-CD40 antibody designed to enhance FcγRIIB binding, aiming to improve tumor response & reduce toxicity: ➡️https://t.co/CVsEzrsvyH⬅️ @sitcancer #SITC24 #ImmunoOnc #Oncology #CTSM
-
-
Mashup Score: 10
Hans-Christian Kolberg, MD, Marienhospital Bottrop, Bottrop, Germany, comments on the results of the NeoMono trial, a Phase II neoadjuvant randomized clinical trial in triple-negative breast cancer patients, highlighting the importance of PD-L1 as a biomarker for immune checkpoint inhibitor therapy. Dr Kolberg notes that despite the trial’s unique design and high PCR rates, particularly in the PD-L1 positive population, no treatment interaction was observed, but PD-L1 remains a strong signal as an important biomarker. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥 Hans-Christian Kolberg, MD, discusses the NeoMono trial in #TNBC at #SABCS24: 🌟High PCR rates in PD-L1+ patients 🌟PD-L1 = key biomarker for immune checkpoint therapy ➡️https://t.co/bxiMcvqhck⬅️ @SABCSSanAntonio #BreastCancer #BCSM #ImmunoOnc #CTSM #TrialUpdates
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 13 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
📢1 week until all things GI cancer are debated virtually at #GDUGI2023! Keep an eye on https://t.co/ys1d8pDAKO for all the updates…💻 @GreatDebatesCME #GDUGI2023 #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/Bj1V9ui2l2
-
-
Mashup Score: 13SABCS 2024 Archives - VJOncology - 13 day(s) ago
VJOncology are excited to attend the upcoming 47th San Antonio Breast Cancer Symposium (SABCS) 2024, bringing you the highly-anticipated trial data and insightful perspectives from leading experts in breast cancer! This international scientific symposium allows for important interactions and exchanges between basic scientists and clinicians devoted to improved diagnosis and treatment of breast cancer. Stay tuned for our coverage of the meeting, and catch up on the 2023 meeting below! VJOncology are
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
Our Collaborators at @VJOncology are in San Antonio for #SABCS24 bringing you the highly-anticipated trial data and insightful perspectives from leading experts in #BreastCancer Find their Coverage here: https://t.co/yORESTUyvO Experts include @KalinskyKevin @matteolambe… https://t.co/7qtugUdaHG https://t.co/lruXvOrwc2
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 13 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
📢1 week until all things GI cancer are debated virtually at #GDUGI2023! Keep an eye on https://t.co/ys1d8pDAKO for all the updates…💻 @GreatDebatesCME #GDUGI2023 #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/Bj1V9ui2l2
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 13 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
📢1 week until all things GI cancer are debated virtually at #GDUGI2023! Keep an eye on https://t.co/ys1d8pDAKO for all the updates…💻 @GreatDebatesCME #GDUGI2023 #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/Bj1V9ui2l2
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 13 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
📢1 week until all things GI cancer are debated virtually at #GDUGI2023! Keep an eye on https://t.co/ys1d8pDAKO for all the updates…💻 @GreatDebatesCME #GDUGI2023 #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/Bj1V9ui2l2
-
RT @OncoAlert: LITESPARK-029 Report with Bora Lim ( @VJOncology) https://t.co/fM553nrRp7 evaluating the efficacy of belzutifan, a HIF-2α…